ArQule Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/9/2019)
| Balance Sheet | Total Assets | 106,676,000.00 | ROE | – |
| Balance Sheet | Total Equity | 78,968,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -12,976,000.00 | – | – |
| Cashflow | Operating Cash Flow | -12,976,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.16 | Div. Yield | – |
| Income | Net Income | -15,482,000.00 | P/E | – |
| Income | Shares Outstanding | 96,762,500.00 | P/B | – |
| Income | Total Revenue | 25,760,000.00 | P/S | – |
Ratios calculated on: –
Company Description
ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.arqule.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more